TERN
Terns Pharmaceuticals, Inc.
$52.95
+0.00 (+0.00%)
At close · May 7
Market Cap
$6.12B
Shares
115,521,157
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2022
Net Income
-$96.21M
-8.3%
FY2025
Operating Margin
-4986%
FY2021
Diluted EPS
-$1.03
+8%
FY2025
Operating Cash Flow
-$82.18M
-17.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| — | — | — | $0 | $1M | |
| $77.89M | $70.11M | $63.5M | $39.62M | $31.31M | |
| $32.24M | $31.76M | $39.06M | $22.41M | $19.55M | |
| $90K | $319K | $292K | $484K | $512K | |
| $110.12M | $101.87M | $102.56M | $62.03M | $50.86M | |
| -$110.12M | -$101.87M | -$102.56M | -$62.03M | -$49.86M | |
| — | — | — | — | -4986% | |
| -$110.03M | -$101.55M | -$102.27M | -$61.55M | -$49.35M | |
| $14.5M | $13.28M | $12.59M | $2.04M | $210K | |
| -$95.63M | -$88.59M | -$89.97M | -$59.99M | -$49.65M | |
| $581K | $260K | $239K | $358K | $508K | |
| -$96.21M | -$88.85M | -$90.21M | -$60.35M | -$50.16M | |
| — | — | — | — | -5015.8% | |
| — | — | — | — | $0 | |
| — | — | — | — | -$50.16M | |
| -$95.67M | -$89.11M | -$89.41M | -$60.83M | -$50.37M | |
| USD/shares | -$1.03 | -$1.12 | -$1.27 | -$1.67 | — |
| USD/shares | -$1.03 | -$1.12 | -$1.27 | -$1.67 | — |
| shares | 93.17M | 79.51M | 71.26M | 36.03M | 22.71M |
| shares | 93.17M | 79.51M | 71.26M | 36.03M | 22.71M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.39×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.68×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2021-12-31 |
|---|---|
| License Fee | $1,000,000 |